Safety and Efficacy of Alogliptin in Indian Participants With Type 2 Diabetes Mellitus
NCT03042325 · Status: WITHDRAWN · Phase: PHASE4 · Type: INTERVENTIONAL
Last updated 2017-10-20
Summary
The purpose of this study is to evaluate the safety and efficacy of alogliptin tablets when given as monotherapy or add on therapy in participants who are on standard care for management of Type 2 Diabetes Mellitus (T2DM).
Conditions
- Diabetes Mellitus, Type 2
Interventions
- DRUG
-
Alogliptin
Alogliptin tablets
Sponsors & Collaborators
- lead INDUSTRY
Principal Investigators
-
Medical Director Clinical Science · Takeda
Study Design
- Allocation
- NA
- Purpose
- TREATMENT
- Masking
- NONE
- Model
- SINGLE_GROUP
Eligibility
- Min Age
- 18 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2017-07-30
- Primary Completion
- 2018-01-15
- Completion
- 2018-01-15
More Related Trials
-
Pharmacokinetics, Pharmacodynamics, and Safety of Alogliptin in Children, Adolescents and Adults With Type 2 Diabetes Mellitus
NCT00957268 ·Status: COMPLETED ·Phase: PHASE1
-
Efficacy and Safety of Alogliptin and Metformin Fixed-Dose Combination in Participants With Type 2 Diabetes
NCT01890122 ·Status: COMPLETED ·Phase: PHASE3
-
Efficacy and Safety of Alogliptin Plus Metformin in Patients With Type 2 Diabetes
NCT01023581 ·Status: COMPLETED ·Phase: PHASE3
-
Efficacy and Safety of Alogliptin Used in Combination With α-glucosidase Inhibitor in Participants With Type 2 Diabetes in Japan
NCT01263483 ·Status: COMPLETED ·Phase: PHASE2/PHASE3
-
Study of Alogliptin Combined With Pioglitazone in Subjects With Type 2 Diabetes Mellitus
NCT00286494 ·Status: COMPLETED ·Phase: PHASE3
-
Efficacy and Safety of Alogliptin in Participants With Type 2 Diabetes in Japan
NCT01263470 ·Status: COMPLETED ·Phase: PHASE2
-
Non-Interventional Study of the Use of Alogliptin and Alogliptin Fixed-Dose Combinations With Pioglitazone and With Metformin in Standard Clinical Practice
NCT02989649 ·Status: TERMINATED
-
Efficacy and Safety of Alogliptin Used Combination With Metformin in Participants With Type 2 Diabetes in Japan
NCT01318109 ·Status: COMPLETED ·Phase: PHASE2/PHASE3
-
Efficacy of Alogliptin and Pioglitazone in Subjects With Type 2 Diabetes Mellitus
NCT00432276 ·Status: COMPLETED ·Phase: PHASE3
-
Efficacy and Safety of Alogliptin Combined With Pioglitazone in Treating Subjects With Type 2 Diabetes Mellitus.
NCT00328627 ·Status: COMPLETED ·Phase: PHASE3
-
Efficacy of Alogliptin and With Pioglitazone in Patients With Type 2 Diabetes.
NCT00655863 ·Status: COMPLETED ·Phase: PHASE3
-
Efficacy and Safety of Alogliptin Plus Metformin Compared to Glipizide Plus Metformin in Patients With Type 2 Diabetes Mellitus
NCT00856284 ·Status: COMPLETED ·Phase: PHASE3
-
Efficacy and Safety of Alogliptin vs. Acarbose in Chinese Type 2 Diabetes Mellitus (T2DM) Patients With High CV Risk or CHD Treated With Aspirin and Inadequately Controlled With Metformin Monotherapy or Drug Naive
NCT03794336 ·Status: COMPLETED ·Phase: PHASE4
-
Efficacy and Safety of Alogliptin Used Combination With Thiazolidine in Participants With Type 2 Diabetes in Japan
NCT01318070 ·Status: COMPLETED ·Phase: PHASE2/PHASE3
-
Long-term Safety Study of Alogliptin Used in Combination With α-glucosidase Inhibitor in Participants With Type 2 Diabetes in Japan
NCT01263509 ·Status: COMPLETED ·Phase: PHASE2/PHASE3
-
Study of Alogliptin Combined With Sulfonylurea in Subjects With Type 2 Diabetes Mellitus.
NCT00286468 ·Status: COMPLETED ·Phase: PHASE3
-
Comparative Study to Evaluate Efficacy and Safety When Metformin Hydrochloride 500 mg Once Daily is Added on to SYR-322 25 mg in Type 2 Diabetic Patients With Inadequate Glycemic Control Despite Treatment With SYR-322 25 mg in Addition to Diet and Exercise Therapy
NCT02068443 ·Status: COMPLETED ·Phase: PHASE3
-
Efficacy and Safety of Alogliptin Used in Combination With Sulfonylurea in Participants With Type 2 Diabetes in Japan
NCT01318083 ·Status: COMPLETED ·Phase: PHASE2/PHASE3
-
Long-term Safety Study of Alogliptin Used in Combination With Thiazolidine in Participants With Type 2 Diabetes in Japan
NCT01318122 ·Status: COMPLETED ·Phase: PHASE2/PHASE3
-
A Non-Interventional Study To Evaluate Diabetes Related Quality Of Life, Frequency And Impact Of Hypoglycemia In T2DM
NCT01523405 ·Status: COMPLETED
-
Long-term Study of Alogliptin as an Add-on to Rapid-Acting Insulin Secretagogues in Type 2 Diabetes
NCT01456130 ·Status: COMPLETED ·Phase: PHASE3
-
Long-term Safety Study of Alogliptin in Participants With Type 2 Diabetes in Japan
NCT01263496 ·Status: COMPLETED ·Phase: PHASE2
-
Efficacy and Safety of Add-On Therapy With Empagliflozin in Patients With Type 2 Diabetes on a Background of Alogliptin and Metformin
NCT07093476 ·Status: RECRUITING ·Phase: PHASE3
-
Safety and Efficacy of Albiglutide in Type 2 Diabetes
NCT00849056 ·Status: COMPLETED ·Phase: PHASE3
-
A Study to Evaluate the Effect of add-on Pioglitazone or Dapagliflozin in Participants With Type 2 Diabetes Mellitus Inadequately Controlled by DPP-4 Inhibitor and Metformin Therapy
NCT03499704 ·Status: COMPLETED ·Phase: PHASE4